12/20
02:03 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/12
02:03 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/4
02:08 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/26
03:07 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/18
03:07 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/15
06:15 am
mrns
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results [Yahoo! Finance]
Medium
Report
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results [Yahoo! Finance]
11/14
10:12 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $4.00 price target on the stock.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $4.00 price target on the stock.
11/14
08:15 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
11/12
07:04 pm
mrns
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
High
Report
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/12
04:00 pm
mrns
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
High
Report
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
11/10
02:03 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/2
02:10 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/29
06:57 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was downgraded by analysts at Truist Financial Co. from a "strong-buy" rating to a "hold" rating.
High
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was downgraded by analysts at Truist Financial Co. from a "strong-buy" rating to a "hold" rating.
10/25
04:22 pm
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
10/25
03:39 pm
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "hold" rating re-affirmed by analysts at TD Cowen.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "hold" rating re-affirmed by analysts at TD Cowen.
10/25
01:44 pm
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Royal Bank of Canada from $3.00 to $1.00. They now have a "sector perform" rating on the stock.
High
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Royal Bank of Canada from $3.00 to $1.00. They now have a "sector perform" rating on the stock.
10/25
12:34 pm
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Cantor Fitzgerald from $13.00 to $4.00. They now have an "overweight" rating on the stock.
High
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Cantor Fitzgerald from $13.00 to $4.00. They now have an "overweight" rating on the stock.
10/25
08:37 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "hold" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $0.50 price target on the stock, down previously from $5.00.
High
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "hold" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $0.50 price target on the stock, down previously from $5.00.
10/24
03:27 pm
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "market perform" rating re-affirmed by analysts at JMP Securities.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "market perform" rating re-affirmed by analysts at JMP Securities.
10/24
01:53 pm
mrns
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options [Yahoo! Finance]
Low
Report
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options [Yahoo! Finance]
10/24
08:00 am
mrns
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
High
Report
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
10/17
07:00 am
mrns
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
Low
Report
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
10/15
04:02 pm
mrns
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens [Yahoo! Finance]
Low
Report
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens [Yahoo! Finance]
10/15
04:00 pm
mrns
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
Medium
Report
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
10/9
07:00 am
mrns
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
Low
Report
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting